Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain

This article describes the kinetic modeling of [11C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET). Positron emission tomography studies were performed in healthy volunteers at placebo conditions and after treatment with clinical doses of moclobemide. In either condition, a two-tissue compartment model (2CM) provided better fits to the data than a one-tissue model. Estimates of k3/k4 values from an unconstrained 2CM were highly variable. In contrast, estimates of the specifically bound radioligand distribution volume (DVB) from an unconstrained 2CM were exceptionally stable, correlated well with the known distribution of MAO-A in the brain (cerebellum <frontal cortex ≈ putamen <temporal cortex ≈ cingulate <thalamus) and thus provided reliable indices of MAO-A density. Total distribution volume (DV) values were also highly stable and not different from those estimated with the Logan approach. Fixing the DV of free and nonspecifically bound radiotracer (DVF + NS) or coupling DVF + NS between brain regions enabled more stable estimates of k3/k4 as compared with an unconstrained 2CM. Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [11C]-harmine binding to MAO-A. The stability and reliability of DVB values obtained from an unconstrained 2CM, together with the computational simplicity associated with this method, support the use of DVB as an appropriate outcome measure for [11C]-harmine. These results indicate the suitability of using [11C]-harmine for quantitative evaluation of MAO-A densities using PET and should enable further studies of potential MAO-A dysregulation in several psychiatric and neurologic illnesses.

[1]  J. Angst,et al.  Efficacy of moclobemide in different patient groups: a meta-analysis of studies , 2005, Psychopharmacology.

[2]  O. Scremin,et al.  Regional cerebral cortical activation in monoamine oxidase A-deficient mice: differential effects of chronic versus acute elevations in serotonin and norepinephrine , 2000, Neuroscience.

[3]  J J DiStefano,et al.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.

[4]  S. Holte,et al.  Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B , 1990 .

[5]  C Burger,et al.  Modeling alternatives for cerebral carbon-11-iomazenil kinetics. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  J J Grome,et al.  The Effects of Serotonin on Local Cerebral Blood Flow , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Z Rattner,et al.  Measurement of Benzodiazepine Receptor Number and Affinity in Humans Using Tracer Kinetic Modeling, Positron Emission Tomography, and [11C]Flumazenil , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  O. Curet,et al.  Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone , 2003, Journal of Pharmacology and Experimental Therapeutics.

[9]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[10]  P. Malherbe,et al.  Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry , 1996, Neuroscience.

[11]  G. Bonvento,et al.  Effects of Electrical Stimulation of the Dorsal Raphe Nucleus on Local Cerebral Blood Flow in the Rat , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  R. Ramsay,et al.  Inhibition of monoamine oxidase A by beta-carboline derivatives. , 1997, Archives of biochemistry and biophysics.

[13]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[14]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  A. Cesura,et al.  Quantitative enzyme radioautography with [3H]Ro 19-6327: Localization of MAO-B in rat CNS, peripheral organs and human brain , 1988 .

[16]  W. Burkard,et al.  Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. , 1989, Journal of neural transmission. Supplementum.

[17]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  N. Volkow,et al.  Monoamine oxidase A imaging in peripheral organs in healthy human subjects , 2003, Synapse.

[19]  N. Volkow,et al.  Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  N. Nair,et al.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. , 1993, Journal of psychiatry & neuroscience : JPN.

[21]  C. D. Arnett,et al.  Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.

[22]  M. Bergström,et al.  MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography , 1997, European Journal of Clinical Pharmacology.

[23]  P. Waldmeier On the reversibility of reversible MAO inhibitors , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  D. Murphy,et al.  Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation , 1979, Psychopharmacology.

[26]  H. Meltzer,et al.  Negative symptoms and platelet monoamine oxidase activity in male schizophrenic patients , 1984, Psychiatry Research.

[27]  Alan A. Wilson,et al.  Facile radiolabelling and purification of 2β‐[O‐11CH3]‐carbomethoxy‐3β‐aryltropanes: Radiotracers for the dopamine transporter , 1994 .

[28]  J. Seibyl,et al.  SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  M. Vila,et al.  Localization of monoamine oxidases in human peripheral tissues. , 1996, Life sciences.

[30]  D. E. Kuhl,et al.  Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  D. Murphy,et al.  Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. , 1972, The American journal of psychiatry.

[32]  M. Youdim,et al.  Platelet monoamine oxidase B: Use and misuse , 1988, Experientia.

[33]  J S Fowler,et al.  Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic Tracers , 1987, Journal of neurochemistry.

[34]  M. Bergström,et al.  Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. , 1997, Nuclear medicine and biology.

[35]  M. Stanley,et al.  Postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls , 1984, Acta psychiatrica Scandinavica.

[36]  G. Cohen,et al.  Monoamine oxidase and oxidative stress at dopaminergic synapses. , 1990, Journal of neural transmission. Supplementum.

[37]  M E Phelps,et al.  Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[39]  J. Marcusson,et al.  Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[40]  U. Holzgrabe,et al.  Allosteric modulators of ligand binding to muscarinic acetylcholine receptors , 1998 .

[41]  H. Akaike A new look at the statistical model identification , 1974 .

[42]  M. Bergström,et al.  11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. , 1997, Nuclear medicine and biology.

[43]  U. Bonnet Moclobemide: therapeutic use and clinical studies. , 2003, CNS drug reviews.

[44]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  Alan A. Wilson,et al.  Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. , 2000, Nuclear medicine and biology.

[46]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[47]  E. Chiu,et al.  Platelet monoamine oxidase activity in Huntington's chorea. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[48]  R. Ramsay,et al.  Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .

[49]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[50]  B. Winblad,et al.  Monoamine oxidase activity and kinetic properties in platelet-rich plasma from controls, chronic alcoholics, and patients with nonalcoholic liver disease. , 1981, Biochemical medicine.

[51]  L. Oreland,et al.  Low platelet monoamine oxidase activity in cigarette smokers. , 1981, Life sciences.

[52]  H. Livingston,et al.  Monoamine Oxidase Inhibitors , 1996 .

[53]  N. Turjanski,et al.  Platelet monoamine oxidase B activity in Parkinson's disease: A re-evaluation , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[54]  D. Wong,et al.  Column-switching HPLC for the analysis of plasma in PET imaging studies. , 2000, Nuclear medicine and biology.

[55]  H. Meltzer,et al.  Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression , 1999, Brain Research.

[56]  K. Leenders,et al.  Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. , 1996, Nuclear medicine and biology.

[57]  J. Saura,et al.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.